PfMPV17与恶性疟原虫体外对alstonine耐药相关
研究通过体外进化获得对alstonine敏感性降低约20倍的恶性疟原虫,全基因组测序发现PfMPV17基因A318P突变,CRISPR/Cas9验证该突变降低alstonine敏感性。线粒体呼吸功能未发现直接关联,但对atovaquone和DSM265耐药的虫株对alstonine敏感性降低,提示alstonine作用与线粒体和/或嘧啶生物合成通路相关。
要点
- PfMPV17 A318P突变与恶性疟原虫体外对alstonine敏感性降低相关。
- 对atovaquone和DSM265耐药的虫株对alstonine敏感性降低。
- 未发现alstonine作用与线粒体呼吸功能直接关联。
核心结论
- PfMPV17与alstonine耐药相关,alstonine作用可能线与线粒体和/或嘧啶生物合成通路相关。
研究设计与样本
- 采用体外进化产生alstonine耐药恶性疟原虫,结合全基因组测序和CRISPR/Cas9基因编辑验证突变。
主要发现
- 体外选择获得对alstonine敏感性降低约20倍的恶性疟原虫。
- 耐药亚克隆全基因组测序发现PfMPV17基因拷贝数变异和A318P点突变。
- 将A318P突变引入野生型恶性疟原虫PfMPV17基因导致alstonine敏感性降低。
- 未发现alstonine作用与线粒体呼吸功能直接关联。
- 对atovaquone和DSM265耐药的转基因恶性疟原虫对alstonine敏感性降低。
临床怎么用
- 本研究为体外实验,尚未提供临床用药推荐。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are an estimated 260 million malaria cases and ∼600 000 deaths annually. Challenges to malaria eradication include the lack of highly effective and broadly applicable vaccines and parasite drug resistance. This is driving the need for new tools, including novel drugs and drug targets. The indoloquinolizidine alkaloid alstonine was previously shown to have in vitro activity against Plasmodium falciparum malaria parasites and a slow-action activity that is different from other slow-action antiplasmodial compounds such as clindamycin. OBJECTIVES: To investigate the action of the antiplasmodial compound alstonine by validating a putative resistance mutation and determining whether the activity of alstonine is linked to the mitochondrial electron transport chain. MATERIALS AND METHODS: In vitro evolution of resistance was used to generate alstonine-resistant P. falciparum, followed by whole-genome sequencing and CRISPR/Cas9 gene editing of wildtype parasites to validate a putative resistance-associated mutation. Links to mitochondrial function were assessed using oxygen consumption rate measurements and activity of alstonine in P. falciparum expressing the yeast dihydroorotate dehydrogenase. RESULTS: P. falciparum parasites were selected with ∼20-fold reduced sensitivity to alstonine compared to wild-type parasites. Whole-genome sequencing of alstonine-resistant P. falciparum sub-clones identified several mutations including a copy number variation and point mutation (A318P) in a gene encoding a putative inner-mitochondrial membrane protein (PfMPV17). Introduction of the A318P mutation into the PfMPV17 gene in wild-type P. falciparum yielded parasites with reduced alstonine sensitivity. While a direct link between alstonine action and mitochondrial respiratory function was not found, a transgenic P. falciparum line resistant to the cytochrome bc1 inhibitor atovaquone and pyrimidine synthesis inhibitor DSM265 had reduced sensitivity to alstonine. CONCLUSIONS: These data demonstrate that PfMPV17 is linked to alstonine resistance and suggest that alstonine action is linked to the mitochondria and/or pyrimidine biosynthesis pathways.
引用
- Macdonald JR, Arnold MS, Luth MR, et al. Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine. J Antimicrob Chemother. 2025. PMID: 40432501. doi:10.1093/jac/dkaf141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。